Nivolumab is a human monoclonal antibody against the immune checkpoint receptor programmed death-1, inhibiting binding to programmed death-ligand 1 or 2 (PD-L1 or PD-L2). This phase 2 study evaluated the efficacy and safety of nivolumab in patients with advanced/recurrent uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma (STS). Patients received nivolumab 240 mg at 2-week intervals. Primary endpoint was objective response rate; secondary endpoints included overall survival, progression-free survival, and safety. PD-L1 expression and microsatellite-instability (MSI) status were analyzed as potential efficacy biomarkers. Objective response rate was 25%, 23%, and 0% in patients with cervical cancer (n = 20), corpus cancer (n = 22), and STS (n = 21), respectively. The lower 80% confidence intervals of objective response rates in patients with cervical or corpus cancer exceeded the threshold rate (5%); the primary endpoint was met in cervical and corpus cancer, but not in STS.
| INTRODUC TI ON
Programmed death-1 is an immune checkpoint receptor expressed by activated T cells. 1 Binding of the ligands PD-L1 or PD-L2 to PD-1 suppresses T-cell function leading to immune escape, where tumor cells can proliferate undetected by immunosurveillance. 1 Clinical trials have shown antibodies against PD-1 or PD-L1 to be effective in blocking tumor immune evasion and inducing tumor regression in several types of cancer, including melanoma, nonsmall cell lung cancer, and renal cell cancer. 1 Some studies of PD-L1 expression have reported PD-L1 positivity in uterine cervical cancer, uterine corpus cancer, and STS, [2] [3] [4] suggesting that these tumor types are potentially responsive to PD-1/PD-L1 blockade therapy. In support of this, the anti-PD-1 antibody pembrolizumab and the anti-PD-L1 antibody atezolizumab have shown antitumor activity in patients with uterine cervical cancer and/or patients with uterine corpus cancer. [5] [6] [7] [8] Nivolumab is a human monoclonal antibody against PD-1 that inhibits the binding of PD-1 to PD-L1 or PD-L2, thereby enhancing the immune response to tumors. 1 Nivolumab has been approved for the treatment of many tumor types in many countries. The aim of this phase 2 study was to evaluate the efficacy and safety of nivolumab in patients with advanced or recurrent uterine cervical cancer, uterine corpus cancer, or STS, which will assist in the decision to proceed to late-phase clinical trials. An exploratory analysis of PD-L1 expression, HPV genotype, and MSI status as potential biomarkers for efficacy was also carried out.
| MATERIAL S AND ME THODS

| Study design
This was a prospective, multicenter, open-label, phase 2 study to evaluate the efficacy and safety of nivolumab in Japanese patients with advanced/recurrent uterine cervical cancer, uterine corpus cancer, or STS.
| Patients
Patients aged ≥18 years with histologically confirmed advanced or recurrent uterine cervical cancer, uterine corpus cancer, or STS not curable by surgical or radiation therapy were eligible. Other main inclusion criteria were: ≥1 previous chemotherapy regimen for advanced/recurrent uterine cervical or corpus cancer, or ≥2 previous chemotherapy regimens for advanced/recurrent STS; ≥1 measurable lesion as defined in the RECIST guidelines, version 1.1; 9 ECOG performance status score of 0 or 1; and adequate hematological, hepatic, and renal function.
Main exclusion criteria were previously receiving antibodies against PD-1, PD-L1, PD-L2, CD137, or CTLA-4, or other therapeutic antibodies or pharmacotherapies for regulation of T cells, and receiving systemic corticosteroids or immunosuppressants within 28 days before enrollment. 
| Treatment
| Study endpoints and assessments
Primary endpoint was ORR, based on the investigator's assessment and defined as the percentage of patients with a best overall response of CR or PR per RECIST. Tumor response was assessed every 6 weeks by chest, abdominal, and pelvic computed tomography/magnetic resonance imaging or other imaging examinations, according to RECIST. 2.5 | Exploratory biomarker study
| Programmed death-ligand 1 expression
Tumor tissue specimens were collected during the screening period (or a preserved specimen was used), stained for PD-L1, and assessed by a pathologist at the central laboratory designated by the sponsor. PD-L1 positivity was defined as PD-L1 expression (detected by the 28-8 PharmDx assay; Dako, Glostrup, Denmark) in ≥1% of tumor cells (tumor proportion score ≥1%).
| Human papilloma virus genotyping and MSI testing
Human papilloma virus genotype testing 10 was offered to patients with uterine cervical cancer. MSI testing (MSI Analysis System; Promega, Madison, WI, USA) was offered to patients with uterine cervical or corpus cancer. For both tests, a tumor tissue specimen was collected during the screening period or a preserved specimen was used.
| Safety
Adverse events were classified according to the Japanese translation of the NCI-Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.
| Statistical methods
A sample size of 18 for each cancer type was calculated to allow a ≥70% 
| Efficacy
The ORR was 25%, 23%, and 0% in patients with cervical cancer, corpus cancer, and STS, respectively ( Table 3 ). The lower limit of the 80% CI of the ORR in patients with cervical or corpus cancer exceeded the threshold ORR (5%) ( Table 3 ).
The 6-month OS rate, median PFS, and Kaplan-Meier curves for OS and PFS for the three cancer cohorts are shown in Table 3 Characteristic Prior regimens of chemotherapy, a n (%) for the target disease that was followed by a confirmed recurrence ≥52 wks after the last dosing.
TA B L E 1 Baseline characteristics of patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma and Figure 1 . Median duration of response could not be estimated for the patients with cervical or corpus cancer who responded (Table 3) .
Tumor size was reduced with nivolumab treatment in more than half of patients with cervical cancer and in almost half of patients with corpus cancer ( 
| Programmed death-ligand 1 status
The ORR in cervical cancer was higher in patients with PD-L1-positive tumors (33%) than in those with PD-L1-negative tumors (0%), despite similar PFS and OS (Table 3 , Figure 3A ,B). In contrast, the ORR in corpus cancer was similar regardless of PD-L1 status (positive, 25% vs negative, 21%), as was PFS (Table 3 , Figure 3D ). Only one patient with STS (leiomyosarcoma) showed PD-L1 expression ≥1% (Table 3 , Figure 3E ,F). Examples of PD-L1 immunostaining in cervical cancer and corpus cancer are shown in Figure 4 .
| Human papilloma virus genotype status
The ORR and PFS were similar between patients with HPV-positive and HPV-negative cervical cancer (Table 3) . Approximately half of patients with cervical cancer who had HPV-positive and PD-L1-positive tumors (3/7 patients) or who had HPV-negative and PD-L1-positive tumors (1/2 patients) responded to nivolumab treatment.
| Microsatellite-instability status
Microsatellite-instability status was determined for eight patients with cervical cancer, all of whom were classified as microsatellite stable (MSS); the ORR in these eight patients was 25% (Table 3) .
MSI status was determined for eight patients with corpus cancer:
the ORR was higher in patients classified as MSI-high (2/2 patients, 100%) than in patients classified as MSS (0/6 patients, 0%) ( Table 3 ).
| Safety
The most common treatment-related AEs were increased aspartate aminotransferase, hypothyroidism, and pruritus in the cervical cancer cohort, pruritus in the corpus cancer cohort, and rash and pruritus in the STS cohort (Table 4) . There were few grade 3 treatment-related AEs, including immune-related AEs. There were no treatment-related type 1 diabetes events. One sudden death, not immune-related or related to nivolumab, occurred in a patient with cervical cancer.
| D ISCUSS I ON
This prospective study showed that nivolumab has acceptable toxicity, with evidence of clinical activity, in patients with uterine cervical or corpus cancer. However, based on ORR, our study did not show clinical activity of nivolumab in STS. Given that the observed ORRs in uterine cervical and corpus cancers exceeded the expected ORR of 19.2%, these results support proceeding to a larger and/or randomized phase 2 or 3 trial of nivolumab in these cancers.
In this study of nivolumab, antitumor activity was observed in patients with uterine cervical or corpus cancer. In patients with cervical cancer, the ORR was 25% (80% CI: 13%-41%). In the published literature, ORRs of 26% have been reported in the TA B L E 2 Pathological classification of patients with uterine cervical cancer, uterine corpus cancer, or soft tissue sarcoma NRG-GY002 study of nivolumab in patients with persistent/recurrent cervical cancer, 16 and 3% in a phase 1/2 study examining ipilimumab (a humanized monoclonal antibody against CTLA-4) in patients with recurrent HPV-related cervical cancer. 17 Median PFS in patients with cervical cancer was 5.6 months in the current study and 5.5 months in the CheckMate 358 study. 15 In patients with corpus cancer, the ORR was 23% (80% CI: 11%-38%). In the published literature, ORRs of 13% have been reported in the KEYNOTE-028 study of pembrolizumab in patients with PD-L1-positive endometrial cancer 7 and in a phase 1a study of atezolizumab in patients with endometrial cancer. and PD-L1-negative tumors responded similarly (25% vs 21%). In a phase 1a study in advanced/recurrent endometrial cancer, the clinical benefit of atezolizumab appeared to increase with higher PD-L1 levels. 8 In contrast, both the CheckMate 358 study 15 and the phase 1/2 ipilimumab study 17 found no relationship between PD-L1 expression and response rates. We note that there did not appear to be a correlation between PD-L1 expression and the neutrophil-to-lymphocyte ratio in the current study (data not shown).
Microsatellite instability has frequently been observed in endometrial adenocarcinomas. 18 In patients with corpus cancer in the current study, the ORR was higher in patients with MSI-high tumors (100%) than in those with MSS tumors (0%), although it should be noted that only two patients were determined to be MSI-high. In the KEYNOTE-028 study, only 1/24 patients with PD-L1-positive endometrial cancer was classified as MSI-high; this patient had a best response of PD. 7 Microsatellite instability has also been detected in cervical squamous cell carcinoma; 18 however, the potential role of MSI as a biomarker in patients with cervical cancer could not be examined in the current study because the eight patients for whom MSI status was determined were all classified as MSS. We note that the US FDA recently granted accelerated approval to pembrolizumab for the treatment of advanced solid tumors in patients with the MSI-high biomarker and to nivolumab for the treatment of colorectal cancer that has progressed after standard chemotherapy in patients with the MSI-high biomarker. 19 These regulatory approvals mark the first approvals of a cancer treatment based on a common biomarker rather than the site of origin of the tumor. 19 Given the small number of patients with uterine cervical cancer for whom HPV status could be determined (12 of 20 patients), it is difficult to evaluate the relationship between HPV status and response to nivolumab in the current study. Studies investigating the relationship between HPV status and response to nivolumab have had mixed results. 20 None of the patients with STS in our study responded to nivolumab, consistent with a previous finding that nivolumab did not show efficacy in 12 patients with advanced uterine leiomyosarcoma. 21 In contrast, a phase 2 study reported that 7/40 patients (18%) with STS responded to pembrolizumab. 22 In that study, 4/10 patients with undifferentiated pleomorphic sarcoma responded (3 PR, 1 CR); two of the four responders expressed PD-L1. 22 In our study, only one patient with STS (leiomyosarcoma) had a PD-L1-positive tumor. Enrollment of larger numbers of patients with various subtypes of STS, in particular those with PD-L1 expression, may
show clinical activity of nivolumab in these cancers.
The safety profile of nivolumab in the present study was favorable and consistent with that observed in previous studies.
11 -14 Limitations of the current study included the small number of patients, especially for the subgroup/biomarker analyses, and the lack of a comparator treatment arm.
In conclusion, this study shows that nivolumab has acceptable toxicity in the three cohorts studied, with evidence of clinical activity, based on ORR, in patients with uterine cervical or corpus cancer, but not in patients with STS. This study provides supportive evidence for a larger and/or randomized phase 2 or 3 study of nivolumab in the treatment of uterine cervical and corpus cancer.
Confirmation of predictive markers such as PD-L1 or MSI-high, as well as assessment of the efficacy of nivolumab in combination with chemotherapy, would assist the development of effective immunotherapy of uterine cervical and corpus cancers.
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